Ann Arbor, MI – According to filings with the U.S. Securities and Exchange Commission, Amplitude Vascular Systems dba AVS Pulse is raising $22,405,460.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Toland played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amplitude Vascular Systems dba AVS Pulse
AVS is an early-stage medical device company that is focused on safely and effectively treating severely calcified arterial disease. AVS is the first company to develop pulsatile intravascular lithotripsy (PIVL), a therapy that is delivered through a balloon-based platform called Pulse. The PULSE IVL System is designed to be the only minimally invasive technology that gently shatters calcium and opens the artery using a single device. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. We are redefining interventional therapy for severely calcified lesions with our Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.

To learn more about Amplitude Vascular Systems dba AVS Pulse, visit http://www.avspulse.com/

Contact:
Mark Toland, Chief Executive Officer
754-755-1530

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved